Role of 99mTc-Bombesin scan in diagnosis and staging of prostate cancer

被引:40
作者
De Vincentis, G
Remediani, S
Varvarigou, AD
Di Santo, G
Iori, F
Laurenti, C
Scopinaro, F
机构
[1] Univ Roma La Sapienza, Policlin Umberto I, Dept Radiol Sci, Nucl Med Sect, I-00161 Rome, Italy
[2] Univ Roma La Sapienza, Dept Urol, Rome, Italy
[3] Natl Ctr Sci Res Demokritos, Athens, Greece
关键词
Tc-99m Bombesin; prostate cancer; prostate cancer scintigraphy; lymph nodes detection;
D O I
10.1089/108497804773391711
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim of this work was to asses whether a novel Tc-99m labeled Bombesin (BN) can play a clinical role in diagnosis and staging of prostate cancer. 14 patients were studied with trans-rectal ultrasonography-guided biopsy, CT and MRI and with Tc-99m BN Scintigraphy. Five patients were also imaged by In-111 Octreotide (O) scan. All the patients but one were submitted to surgery and final diagnosis was reached by pathology, taken as the gold standard method. Two patients showed benign adenoma and 12 patients showed cancer at biopsy. Tc-99m BN SPECT was positive in all 12 patients with cancer. Four of these patients also showed pelvic focal uptake, referred to inguinal lymph-nodal involvement. MRI and CT provided similar findings in only three cases. Pathologic evaluation after operation confirmed the invasion of nodes in all four subjects. Both Tc-99m BN and In-111 O scans provided normal findings in the two subjects affected by benign adenoma, while In-111 O was positive in only two of three patients with cancer and was always unable to detect nodal invasion. These preliminary data suggest that Tc-99m BN SPECT scan could be useful to detect primary prostate cancer and to reveal loco-regional node involvement.
引用
收藏
页码:81 / 84
页数:4
相关论文
共 19 条
[1]  
Aprikian AG, 1997, INT J CANCER, V72, P498, DOI 10.1002/(SICI)1097-0215(19970729)72:3<498::AID-IJC19>3.3.CO
[2]  
2-P
[3]  
BOLOGNA M, 1989, CANCER, V63, P1714
[4]   Phase I trial of technetium [Leu13] bombesin as cancer seeking agent:: Possible scintigraphic guide for surgery? [J].
De Vincentis, G ;
Scopinaro, F ;
Varvarigou, A ;
Ussof, W ;
Schillaci, O ;
Archimandritis, S ;
Corleto, V ;
Longo, F ;
Delle Fave, G .
TUMORI JOURNAL, 2002, 88 (03) :S28-S30
[5]   Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast [J].
Gugger, M ;
Reubi, JC .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (06) :2067-2076
[6]   PROSTATIC-CARCINOMA - STAGING BY CLINICAL-ASSESSMENT, CT, AND MR IMAGING [J].
HRICAK, H ;
DOOMS, GC ;
JEFFREY, RB ;
AVALLONE, A ;
JACOBS, D ;
BENTON, WK ;
NARAYAN, P ;
TANAGHO, EA .
RADIOLOGY, 1987, 162 (02) :331-336
[7]   Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional TI-weighted magnetization-prepared rapid gradient-echo sequence [J].
Jager, GJ ;
Barentsz, JO ;
Oosterhof, GO ;
Witjes, JA ;
Ruijs, SJH .
AMERICAN JOURNAL OF ROENTGENOLOGY, 1996, 167 (06) :1503-1507
[8]   Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II [J].
Jungwirth, A ;
Pinski, J ;
Galvan, G ;
Halmos, G ;
Szepeshazi, K ;
Cai, RZ ;
Groot, K ;
VadilloBuenfil, M ;
Schally, AV .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (07) :1141-1148
[9]   ProstaScint scan for staging prostate cancer [J].
Lange, PH .
UROLOGY, 2001, 57 (03) :402-406
[10]  
Markwalder R, 1999, CANCER RES, V59, P1152